T1 some use 20/20/20 for 20g/L of M spike (rather than g/dL) but 20/2/20 just fine! #mmsm

T2 two important SMM trials- QUIRIDEX and E3A06 #mmsm

T2 QUIRIDEX 119 pts PFS, Survival benefit for SMM rx up to 2 yr of len with dex HR 0.28 doi: 10.1016/S1470-2045(16)30124-3 #mmsm

T2 E3A06 asked if you need dex at all. Used MRI to exclude pts with true MM; 244 pts in all #mmsm

T2 E3A06 rx-len 25 mg days 1-21 indefinitely vs observation. At 3 yrs, PFS 91% in Len group, 66% in observation #mmsm

T2 E3A06 benefited high risk SMM. Low risk probably can continue on observation #mmsm

T2 Response rate to len 47% in E3A06 #mmsm

T3 EAA173: 1. does adding dara to L + D boost response rate,slow down progression? 2. Dex for 1 year -increase response? #mmsm

T3 DETER trial-focusing on high risk SMM only. 2yr total treatment. 288 participants NCT03937635 #mmsm

T3 DETER EAA173; using MRI and PET to rule out actual MM at enrollment #mmsm

T3 DETER: studying MRD rates after 1 and 2 yr on treatment. Comparing flow and NGS #mmsm

T3 DETER will help decide if triplet beats doublet in SMM. #mmsm

T3 DETER Assessing quality of life and toxicity-subjects get to use ePRO to report side effects. #mmsm

T4 other approaches in SMM- vaccines (NCT01718899) #mmsm

T4 ASCENT: Aggressive Smoldering Curative Approach Evaluating Novel Therapies: use MM treatment to stop SMM progression #mmsm

T4 ASCENT: KRD-6 cycles induction; 6 cycles consolidation; 12 cycles of maintenance NCT03289299 #mmsm

T0: SLIM-CRAB: S=60%; Li=>100 FLC ratio; M=MRI >1 focal lesion plus CRAB #mmsm

Cleaning N95 without destroying it. #PPE

multiplemyelomahub.com/a/K9

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma thelancet.com/journals/lanha…